The world’s first malaria vaccine, developed by GlaxoSmithKline, provides some protection after three doses but its effect dwindles to almost nothing after seven years, scientists said on Wednesday.
Publishing a long-term study of the vaccine - called RTS,S or Mosquirix and designed for children in Africa where the disease claims most of its victims - researchers said the decline in its efficacy over time is fastest in children living in areas with higher than average rates of malaria.
